🔴 Neumora Therapeutics is trading 10.53% down today as coverage points to failed Phase 3 depression trials

Neumora Therapeutics is trading $1.02 (-10.53%) lower, with no new company-specific announcement, earnings release, or analyst action clearly explaining the decline.

• Continued declining from $1.33 on September 1, 2026, to $1.14 on September 10, 2026.
• Recent coverage points to June’s failed Phase 3 depression trials and workforce reduction.
• The broader market is rising, so the move is not aligned with overall index sentiment.